{
    "id": 26166,
    "fullName": "ERCC1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ERCC1 positive indicates the presence of the ERCC1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2067,
        "geneSymbol": "ERCC1",
        "terms": [
            "ERCC1",
            "COFS4",
            "RAD10",
            "UV20"
        ]
    },
    "variant": "positive",
    "createDate": "03/22/2017",
    "updateDate": "03/22/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10321,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ercc1 expression was associated with no response (p=0.033) to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy in patients with muscle-invasive urothelial bladder cancer (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).",
            "molecularProfile": {
                "id": 27355,
                "profileName": "ERCC1 positive"
            },
            "therapy": {
                "id": 5462,
                "therapyName": "Cisplatin + Gemcitabine + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 6477,
                "name": "invasive bladder transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8305,
                    "pubMedId": null,
                    "title": "Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase II study.",
                    "url": "http://meetinglibrary.asco.org/content/179076-197"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27355,
            "profileName": "ERCC1 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}